Brief: Mesoblast Says Raises A$260 Million For Ryoncil Commercial Launch
14/01/2025 01:25
Jan 14 (Reuters) - Mesoblast MSB.AX :
* RAISES A$260 MILLION FOR RYONCIL COMMERCIAL LAUNCH
* PLACEMENT AT A$2.50 PER SHARE
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M